Would like to have some spare $'s, as the momentum is definitely positive. Admittedly they are spending more money, though it is a necessity as they grow their footprint to service foreign markets, and have product available in these jurisdictions. R&D grant was a large percentage of cash flow, and forecast ineligibility for FY21 should be offset by the gain in sales revenue. Management appear to have a downbeat forward forecast, but are positioning for growth with the supply partnerships they are building.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.90M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.5¢ | $22.81K | 62.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2882 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 3086 | 1 |
View Market Depth
| Last trade - 15.50pm 07/07/2025 (20 minute delay) ? |
| GSS (ASX) Chart |